文献速递妇科

累及野放疗治疗复发性卵巢癌:多机构前瞻性II期试验结果

Involved-field radiation therapy for recurrent ovarian cancer: Results of a multi-institutional prospective phase II trial.
PubMed 文献 · Gynecol Oncol · 2018-08-24

这项多机构前瞻性II期试验评估累及野放疗(IFRT)对局部局限的复发性或持续性上皮性卵巢癌的疗效与安全性,纳入30例患者,主要终点无进展生存期未达到;IFRT耐受良好,总缓解率85.7%,完全缓解率50%,中位无进展生存期7个月,2年无进展生存率39.3%,3年局部控制率84.4%、总生存率55.8%,作者认为IFRT对野内肿瘤控制可能安全有效,并计划开展更大规模多中心II期前瞻性研究。

要点

  • 30例局部局限复发性或持续性上皮性卵巢癌患者接受IFRT,剂量≥45 Gy,边缘10-15 mm。
  • 未观察到≥2级急性毒性,放疗后10个月报告1例3级腹痛。
  • 中位随访28个月,中位无进展生存期7个月,2年无进展生存率39.3%。

核心结论

  • 尽管主要终点未达到,IFRT对转移灶数量有限的持续性上皮性卵巢癌患者的野内肿瘤控制可能安全有效。
  • 作者计划开展更大规模的多中心II期前瞻性研究。

研究设计与样本

  • 多机构前瞻性II期试验,纳入适合在复发诊断时或挽救治疗后接受IFRT的复发性上皮性卵巢癌患者。
  • 2014年至2016年共入组30例患者,平均每例5.7个转移灶;17例接受三维适形放疗,13例接受调强放疗。
  • IFRT剂量≥45 Gy,标准影像上边缘10-15 mm;主要终点为无进展生存期,次要终点为安全性、缓解率、局部控制和总生存期。

主要发现

  • IFRT在所有患者中耐受良好,未观察到≥2级急性毒性;放疗后10个月报告1例3级腹痛。
  • 总缓解率为85.7%,完全缓解率为50%。
  • 中位随访28个月(范围17-42个月),中位无进展生存期为7个月,2年无进展生存率为39.3%。
  • IFRT后发生野内疾病进展的16例患者中,6例以重复IFRT作为挽救治疗获得成功。
  • 3年局部控制率为84.4%,3年总生存率为55.8%。

局限性

  • 原文指出主要终点未达到。
  • 原文在结论中提出计划开展更大规模的多中心II期前瞻性研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the efficacy and safety of involved-field radiation therapy (IFRT) in patients with locoregionally confined recurrent or persistent epithelial ovarian cancer. METHODS: This study included patients with recurrent epithelial ovarian cancer eligible for IFRT either during diagnosis of the recurrence or after salvage therapies. IFRT was performed at a dose of ≥45 Gy for all tumors with 10-15-mm margins as seen on standard imaging. The primary endpoint was progression-free survival (PFS); the secondary endpoints were safety, response rate, local control, and overall survival (OS). RESULTS: Thirty patients with a mean number of 5.7 metastatic lesions each were enrolled between 2014 and 2016. Seventeen were treated with 3-D conformal radiation therapy (RT) and 13 with intensity-modulated RT. IFRT was well tolerated in all patients, and acute toxicity ≥ grade 2 was not observed. One case of grade 3 abdominal pain was reported 10 months post-RT. The overall and complete response rates were 85.7% and 50%, respectively. After a median follow-up of 28 (range, 17-42) months, the median PFS was 7 months. The 2-year PFS rate was 39.3%. Six of the 16 patients who developed outfield disease progression after IFRT were successfully treated with repeat IFRT as salvage treatment. The 3-year local control and OS rates were 84.4% and 55.8%, respectively. CONCLUSIONS: Although the primary endpoint was not met, IFRT might be safe and effective for in-field tumor control in patients with persistent epithelial ovarian cancer with a limited number of metastatic foci. We plan to conduct a larger scale multi-center phase II prospective study.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Chang JS, Kim SW, Kim YJ, et al. Involved-field radiation therapy for recurrent ovarian cancer: Results of a multi-institutional prospective phase II trial. Gynecol Oncol. 2018. PMID: 30146110. doi:10.1016/j.ygyno.2018.08.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。